Patents by Inventor Kiyomi Ohba

Kiyomi Ohba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11890288
    Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.
    Type: Grant
    Filed: July 20, 2023
    Date of Patent: February 6, 2024
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kiyomi Ohba, Yasuki Niwa, Tetsuji Matsudaira, Maiko Hamada, Ryuta Yamazaki, Tatsuya Ibuki
  • Publication number: 20230364105
    Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.
    Type: Application
    Filed: July 20, 2023
    Publication date: November 16, 2023
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kiyomi OHBA, Yasuki NIWA, Tetsuji MATSUDAIRA, Maiko HAMADA, Ryuta YAMAZAKI, Tatsuya IBUKI
  • Publication number: 20230146717
    Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.
    Type: Application
    Filed: February 5, 2021
    Publication date: May 11, 2023
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kiyomi OHBA, Yasuki NIWA, Tetsuji MATSUDAIRA, Maiko HAMADA, Ryuta YAMAZAKI, Tatsuya IBUKI
  • Patent number: 11542273
    Abstract: Provided are a compound superior in a cytotoxic action on cancer cells, an action inducing degradation of BET protein in cancer cells, and an inhibitory action on the binding of BET protein and acetylated histone, and useful as an anticancer agent, a BET protein degradation inducer or a BET protein inhibitor. A compound represented by the following formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: July 4, 2019
    Date of Patent: January 3, 2023
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Ryuta Yamazaki, Tatsuya Ibuki, Yuichi Sawaguchi, Kiyomi Ohba, Maiko Hamada, Yasuki Niwa, Yuko Ishida, Hideto Maruyama, Shiki Matsuki, Minoru Tanaka
  • Publication number: 20210284654
    Abstract: Provided are a compound superior in a cytotoxic action on cancer cells, an action inducing degradation of BET protein in cancer cells, and an inhibitory action on the binding of BET protein and acetylated histone, and useful as an anticancer agent, a BET protein degradation inducer or a BET protein inhibitor.
    Type: Application
    Filed: July 4, 2019
    Publication date: September 16, 2021
    Applicants: MITSUBISHI TANABE PHARMA CORPORATION, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Ryuta YAMAZAKI, Tatsuya IBUKI, Yuichi SAWAGUCHI, Kiyomi OHBA, Maiko HAMADA, Yasuki NIWA, Yuko ISHIDA, Hideto MARUYAMA, Shiki MATSUKI, Minoru TANAKA
  • Patent number: 7531655
    Abstract: There are disclosed a large conductance calcium-activated K channel opener comprising a compound of the formula (I): wherein ring A is a 5-membered heterocyclic ring containing any one of O, N or S, which ring may be substituted by R4, R1 is aryl, heterocyclic or heterocycle-substituted carbonyl; R2 is hydrogen, halogen, carboxy, amino, alkyl, alkoxycarbonyl, alkenyl or cycloalkyl; R3 is aryl, heterocyclic or alkyl; and R4 is hydrogen or alkyl, each of substituents may be substituted, or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: May 12, 2009
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Toshihiro Hosaka, Mari Kusama, Kiyomi Ohba, Rikako Kono, Shuntarou Kohnomi
  • Publication number: 20060135597
    Abstract: There are disclosed a large conductance calcium-activated K channel opener comprising a compound of the formula (I): wherein ring A is a 5-membered heterocyclic ring containing any one of O, N or S, which ring may be substituted by R4, R1 is aryl, heterocyclic or heterocycle-substituted carbonyl; R2 is hydrogen, halogen, carboxy, amino, alkyl, alkoxycarbonyl, alkenyl or cycloalkyl; R3 is aryl, heterocyclic or alkyl; and R4 is hydrogen or alkyl, each of substituents may be substituted, or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: October 15, 2002
    Publication date: June 22, 2006
    Applicant: Tanabe Seiyaku Co, Ltd.
    Inventors: Toshihiro Hosaka, Mari Kusama, Kiyomi Ohba, Rikako Kono, Shuntarou Kohnomi